Householder Group Estate & Retirement Specialist’s Celldex Therapeutics CLDX Stock Holding History

Householder Group Estate & Retirement Specialist’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11	Closed	–	–	658
2024 Q3	$0	Buy	+11	New	+$419	﹤0.01%	1185
2024 Q2	–	Sell	-11	Closed	-$462	–	1218
2024 Q1	$462	Hold	11	–	–	﹤0.01%	1161
2023 Q4	$0	Hold	11	–	–	﹤0.01%	1163
2023 Q3	$303	Buy	+11	New	+$345	﹤0.01%	1215
2023 Q1	$0	Hold	11	–	–	﹤0.01%	1236
2022 Q4	$0	Hold	11	–	–	﹤0.01%	455
2022 Q3	$0	Buy	+11	New	+$337	﹤0.01%	1100

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Householder Group Estate & Retirement Specialist's CLDX Position: Q4 2024 in Review

Householder Group Estate & Retirement Specialist sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 11 shares.

Householder Group Estate & Retirement Specialist first reported a position in CLDX in Q3 2022 and held it in 7 quarters. The position peaked at $462 in Q1 2024. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

Householder Group Estate & Retirement Specialist reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
Householder Group Estate & Retirement Specialist sold 11 Celldex Therapeutics shares in Q4 2024.
Householder Group Estate & Retirement Specialist first reported a position in Celldex Therapeutics in Q3 2022 and held it in 7 quarters.
Householder Group Estate & Retirement Specialist's Celldex Therapeutics position peaked at $462 in Q1 2024.
174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Householder Group Estate & Retirement Specialist's 13F filing for Q4 2024, filed 15 Jan 2025.